Over the past decades, starting in the late 1980s, advancements in molecular imaging (i.e. PET) have dramatically changed the landscape of schizophrenia treatment with antipsychotics. These technologies have shed light on the interplay between drug target engagement and clinical outcomes, leading to the establishment of a receptor occupancy-based therapeutic range for antipsychotics. However, the role and significance of Therapeutic Drug Monitoring (TDM) remain controversial, with many clinicians underestimating their importance. Moreover, TDM has faced challenges such as unclear reporting of drug-specific therapeutic reference ranges in the literature.
No takes yet. Share an insight, caveat, or question.
X.M. Hart (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: